Meet Akiri's leaders

 

Tackling the toughest challenges in healthcare requires leaders who are leading the charge to architect new networks. Who are committed to innovating in ways that empowers patients, providers and physicians. Who understand the industry’s structure – and can’t wait to transform it. 

That’s why Akiri is attracting talented executives, engineers, developers, and subject-matter experts from Apple, Cisco, GE Healthcare, Stanford, VMware, and other recognized market innovators. They include:

 
  David. A Watson  | Chief Executive Officer  David is Chief Executive Officer at Akiri. A healthcare IT visionary, he brings more than 30 years of healthcare and technology experience to Akiri. David has demonstrated his passion for applying technology to healthcare innovation at California Integrated Data Exchange, Kaiser Permanente, MedeAnalytcis, and Oracle, among other companies. As Kaiser Permanente CTO, he was the prime architect of its HealthConnect initiative and engineered one of the most successful large-scale clinical system deployments to date. In addition to serving in the U.S. Marines, David also held positions as Global VP of Healthcare Product Strategy at Oracle and COO at healthcare information technology (HIT) company SSI Group. He currently sits on the Board of Directors at Shield Healthcare and is a member of the Information Convergence Advisory Board at New Leaf Venture Partners. David earned a BA of Economics from the University of Southern California and graduated from the executive development program at The Wharton School of the University of Pennsylvania.

David. A Watson | Chief Executive Officer

David is Chief Executive Officer at Akiri. A healthcare IT visionary, he brings more than 30 years of healthcare and technology experience to Akiri. David has demonstrated his passion for applying technology to healthcare innovation at California Integrated Data Exchange, Kaiser Permanente, MedeAnalytcis, and Oracle, among other companies. As Kaiser Permanente CTO, he was the prime architect of its HealthConnect initiative and engineered one of the most successful large-scale clinical system deployments to date. In addition to serving in the U.S. Marines, David also held positions as Global VP of Healthcare Product Strategy at Oracle and COO at healthcare information technology (HIT) company SSI Group. He currently sits on the Board of Directors at Shield Healthcare and is a member of the Information Convergence Advisory Board at New Leaf Venture Partners. David earned a BA of Economics from the University of Southern California and graduated from the executive development program at The Wharton School of the University of Pennsylvania.

  Douglass Given MD, PhD  | Chairman  An internist and infectious diseases doctor by background, Doug has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt, a serial entrepreneur, and a venture capitalist. He led five biotech companies as CEO, including Progenitor (NASDAQ:PGEN), NeoRx (NASDAQ:NERX), Via Pharmaceuticals (NASDAQ:VIAP), Vivaldi Biosciences Inc. and Mercator Genetics Inc. Doug is Managing Partner at Health2047 Capital Partners. Doug served as Health2047 Inc.’s Chief Executive from its founding in August of 2015 until January 2018. Previously, he spent more than a decade in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC through five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999-2015. An experienced board member, Doug currently serves as a Director at Health2047 Inc. and board Chair at both Akiri Inc. and Arrowhead Pharmaceuticals Inc. He recently served as board Chair and CEO at Vivaldi Biosciences Inc. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Harvard School of Public Health, and The Houston Methodist Research Institute. Doug received MD and PhD (Virology) degrees from the University of Chicago, an MBA from the Wharton School at the University of Pennsylvania, was a Clinical and Research Fellow at Massachusetts General Hospital and Harvard Medical School, and an Attending Physician and professor at Indiana University School of Medicine.

Douglass Given MD, PhD | Chairman

An internist and infectious diseases doctor by background, Doug has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt, a serial entrepreneur, and a venture capitalist. He led five biotech companies as CEO, including Progenitor (NASDAQ:PGEN), NeoRx (NASDAQ:NERX), Via Pharmaceuticals (NASDAQ:VIAP), Vivaldi Biosciences Inc. and Mercator Genetics Inc. Doug is Managing Partner at Health2047 Capital Partners. Doug served as Health2047 Inc.’s Chief Executive from its founding in August of 2015 until January 2018. Previously, he spent more than a decade in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC through five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999-2015. An experienced board member, Doug currently serves as a Director at Health2047 Inc. and board Chair at both Akiri Inc. and Arrowhead Pharmaceuticals Inc. He recently served as board Chair and CEO at Vivaldi Biosciences Inc. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Harvard School of Public Health, and The Houston Methodist Research Institute. Doug received MD and PhD (Virology) degrees from the University of Chicago, an MBA from the Wharton School at the University of Pennsylvania, was a Clinical and Research Fellow at Massachusetts General Hospital and Harvard Medical School, and an Attending Physician and professor at Indiana University School of Medicine.

  Daphne Li  | Chief Operating Officer  Daphne is Chief Operating Officer at Akiri, and Managing Director of Business Acceleration for Health2047. During her career, she has helped launch and scale numerous technology-based startups as well as identify and develop new growth areas for Fortune 500 brands. Her passion for scaling companies started at Bain & Company where she served on the business acceleration team, helping early-stage companies develop business models, secure investments, launch products, and scale operations. Prior to joining Health2047, Daphne was Senior Vice President and General Manager of Enterprise at SaaS platform provider Upwork where she grew new sales by 850%. She also led marketing and product management at ADP, transforming a shrinking claims business into a SaaS platform and data business that was sold for $1B. Additionally, as Director of Strategy for Apple’s $1.2B Education group, Daphne forged strategic partnerships, co-created a new sales model, and helped redefine Apple’s education market offering. She holds both an MBA and a BA in Economics from Stanford.

Daphne Li | Chief Operating Officer

Daphne is Chief Operating Officer at Akiri, and Managing Director of Business Acceleration for Health2047. During her career, she has helped launch and scale numerous technology-based startups as well as identify and develop new growth areas for Fortune 500 brands. Her passion for scaling companies started at Bain & Company where she served on the business acceleration team, helping early-stage companies develop business models, secure investments, launch products, and scale operations. Prior to joining Health2047, Daphne was Senior Vice President and General Manager of Enterprise at SaaS platform provider Upwork where she grew new sales by 850%. She also led marketing and product management at ADP, transforming a shrinking claims business into a SaaS platform and data business that was sold for $1B. Additionally, as Director of Strategy for Apple’s $1.2B Education group, Daphne forged strategic partnerships, co-created a new sales model, and helped redefine Apple’s education market offering. She holds both an MBA and a BA in Economics from Stanford.

 
  Mark Bagnall  | Chief Financial Officer  Mark is CFO at Akiri, bringing his biotech expertise in rare and metabolic diseases and in clinical diagnostics. Previously, Mark co-founded Naia Pharmaceuticals, where he developed two new pharmaceutical development companies targeting both mature and emerging markets. He has served as CFO and COO of several public and private biotech companies. Mark is a member of the Board of Directors of medical diagnostic company Ativa Medical, Inc., and Chairman of the Board of infectious disease diagnostics company XCR Dx. As President and CEO at Genturadx, Mark restructured and internationally relocated the organization, growing the team by 900 percent before acquisition. He earned his BS in Finance from UC Berkeley’s Walter A. Haas School of Business.

Mark Bagnall | Chief Financial Officer

Mark is CFO at Akiri, bringing his biotech expertise in rare and metabolic diseases and in clinical diagnostics. Previously, Mark co-founded Naia Pharmaceuticals, where he developed two new pharmaceutical development companies targeting both mature and emerging markets. He has served as CFO and COO of several public and private biotech companies. Mark is a member of the Board of Directors of medical diagnostic company Ativa Medical, Inc., and Chairman of the Board of infectious disease diagnostics company XCR Dx. As President and CEO at Genturadx, Mark restructured and internationally relocated the organization, growing the team by 900 percent before acquisition. He earned his BS in Finance from UC Berkeley’s Walter A. Haas School of Business.

  Nitin Saxena  | Vice President, Engineering  Nitin is Vice President of Engineering at Akiri. A software engineering executive with full-stack experience leading and building products in diverse technology spaces, Nitin has a track record of scaling the engineering methodology to build a cadence of continuous delivery. At Cisco Systems, Nitin served as Senior Director of Software Development for the Cisco DNA Center Platform. As Senior Director of Engineering at EMC, he co-founded and headed engineering for EMC ViPR, managing every aspect of architecture. Nitin was also the Senior Manager of Research and Development at VMware, where he managed efforts on VMware vCenter and cloud management platform services. Previous to multiple senior software development roles at Cisco, Nitin was an exec-level software engineer for India-based companies River Run Software Group, Tata Unisys and HCL Infosystems. Nitin earned a BE from the Indian Institute of Technology, Roorkee, and an MBA from UMass Amherst.

Nitin Saxena | Vice President, Engineering

Nitin is Vice President of Engineering at Akiri. A software engineering executive with full-stack experience leading and building products in diverse technology spaces, Nitin has a track record of scaling the engineering methodology to build a cadence of continuous delivery. At Cisco Systems, Nitin served as Senior Director of Software Development for the Cisco DNA Center Platform. As Senior Director of Engineering at EMC, he co-founded and headed engineering for EMC ViPR, managing every aspect of architecture. Nitin was also the Senior Manager of Research and Development at VMware, where he managed efforts on VMware vCenter and cloud management platform services. Previous to multiple senior software development roles at Cisco, Nitin was an exec-level software engineer for India-based companies River Run Software Group, Tata Unisys and HCL Infosystems. Nitin earned a BE from the Indian Institute of Technology, Roorkee, and an MBA from UMass Amherst.